A) Cardiac ejection fraction (EF) at early (1-2 weeks) and late (4 week) timepoints post-MI. A6 PREMI exhibits significantly greater preservation of EF compared to A6-MI and VEH treated mice at an early timepoint. At late followup (4 weeks), only A6 PREMI animals exhibited significantly higher EF than VEH-treated controls, indicating the importance of pre-treatment with A6. B) Caspase activity blunted by A6 treatment. Caspase activity measured in hearts after two weeks of continuous treatment with either A6 (10ng/kg/d) or VEH solution. Note the significantly reduced caspase activity in A6-MI hearts compared to positive control (PC, Doxorubicin-treated hearts), whereas VEH-MI hearts were not significantly different from PC hearts. In addition, negative control hearts had significantly lower caspase activity levels than VEH-MI hearts, but not A6-MI hearts.